For biotechs like MSB with several products in the pipeline and trials at various stages, if they can commercialize any one of them so they are at least self-sustaining (or near so) in terms of cash-flow, that really underpins confidence IMHO. Any company really. Less periodic worries about raising capital, potential dilution, etc. For the company as well as investors. Partnering on (very expensive) trials is probably still necessary or desirable. But sustainable funding of basic operations, with some overhead liquid operating capital for smaller trials or trial contributions, is certainly something to shoot for.
I'm unsure which msb product would be a potential candidate in that regard.
But I generally agree for a company looking at an erosion of operating cash, squeezing potential partners (whose due diligence no doubt informs them about a company's financial position) when they might provide key operating cash stability...is a tricky business.
MSB Price at posting:
$2.10 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)